Stalpex contains 50/500 mcg salmeterol xinafoate/
fluticasone propionate dose inhalation powder
Stalpex is indicated for use in patients with severe asthma 12 years of age and older only
Regular treatment of patients with severe asthma, where use of a combination product (long-acting ß2 agonist and inhaled corticosteroid) is appropriate:
Symptomatic treatment of patients with a FEV1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, with significant symptoms despite regular bronchodilator therapy
One inhalation twice daily. Once control of asthma is attained, treatment should be reviewed and consideration given to whether patients should be stepped down to a lower dose ICS/LABA combination or ICS alone
One inhalation twice daily
Stalpex has a
50% lower acquisition cost
than the equivalent Seretide® pack 1
lowest cost available of all dry powder inhaler
salmeterol/fluticasone propionate 50/500 products.1
Sources: BNF May 20211
Prices correct at time of development but are subject to change without prior notice. E&OE.
Prescribe Stalpex by brand to ensure:
Your patients get the device
You get the full acquisition cost savings for
Your health economy gets the full
acquisition cost savings
Stalpex 50/500 mcg offers an equivalent user
experience to Seretide® Accuhaler®2-5
The same active substance as Seretide® Accuhaler®2,4,5
Equivalent strength to 50/500 mcg Seretide® Accuhaler® dose4
A functionally equivalent DPI device3
Stalpex has been shown to deliver an equivalent dose to Seretide® Accuhaler® in equivalence studies4
…branching out in a
Glenmark can provide you with estimates of financial savings for your health economy. To find out how much your health authority could save, click on the link below to arrange an appointment.Contact Us
We’re proud of our work designed to make a difference in respiratory medicine. Visit our site to find out more and access free education resources.Explore now
We are committed to ensuring Stalpex is available to order
from the moment a new customer comes on board:
When you prescribe Stalpex by brand, your patients have access to clear information and support to help ensure they take their medication correctly.
The Stalpex dedicated patient website contains information and support for patients prescribed Stalpex. Here they will find guidance
on how to use their inhaler, answers
to FAQs and links to trusted websites.
The website also highlights the
recent change in inhaler design,
(and how both shapes of inhalers are bioequivalent with no change to inhaler technique).3
Click here to view.
You can use it to facilitate Stalpex device training with your patients.
The video can be accessed directly by patients prescribed Stalpex on the patient site.
Seretide® and Accuhaler®are registered trademarks of the GlaxoSmithKline
group of companies.
Stalpex® is a registered trademark of Glenmark Pharmaceuticals Europe Limited.
PIP code: Stalpex 50/500 mcg – 4098661
© 2021 Glenmark Pharmaceuticals Europe Ltd. All rights reserved.
Date of preparation: June 2021 PP-UK-STAL-0016 V3
Adverse events should be reported.
Reporting forms and information can be found at
Adverse events should also be reported to firstname.lastname@example.org
or call 0800 458 0383.